Free Trial
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

MoonLake Immunotherapeutics logo
$56.23 -0.77 (-1.35%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

Key Stats

Today's Range
$56.18
$57.63
50-Day Range
$46.37
$61.12
52-Week Range
$31.42
$61.87
Volume
65,377 shs
Average Volume
487,288 shs
Market Capitalization
$3.61 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.43
Consensus Rating
Moderate Buy

Company Overview

MoonLake Immunotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

MLTX MarketRank™: 

MoonLake Immunotherapeutics scored higher than 52% of companies evaluated by MarketBeat, and ranked 567th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    MoonLake Immunotherapeutics has a consensus price target of $74.43, representing about 30.6% upside from its current price of $57.00.

  • Amount of Analyst Coverage

    MoonLake Immunotherapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about MoonLake Immunotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MoonLake Immunotherapeutics is -20.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MoonLake Immunotherapeutics is -20.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MoonLake Immunotherapeutics has a P/B Ratio of 8.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about MoonLake Immunotherapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.72% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 12.40%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    MoonLake Immunotherapeutics does not currently pay a dividend.

  • Dividend Growth

    MoonLake Immunotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.72% of the float of MoonLake Immunotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in MoonLake Immunotherapeutics has recently decreased by 12.40%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    MoonLake Immunotherapeutics has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for MoonLake Immunotherapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    6 people have searched for MLTX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.05% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MoonLake Immunotherapeutics' insider trading history.
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MLTX Stock News Headlines

Cantor Fitzgerald Has Weak Outlook for MLTX FY2025 Earnings
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
MoonLake Immunotherapeutics (MLTX): A Bull Case Theory
See More Headlines

MLTX Stock Analysis - Frequently Asked Questions

MoonLake Immunotherapeutics' stock was trading at $54.15 on January 1st, 2025. Since then, MLTX shares have increased by 5.3% and is now trading at $57.00.

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by $0.14.

MoonLake Immunotherapeutics' top institutional investors include Westfield Capital Management Co. LP (1.97%), Federated Hermes Inc. (1.95%), Alliancebernstein L.P. (1.78%) and Hood River Capital Management LLC (1.06%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Matthias Bodenstedt, Simon Sturge and Kristian Reich.
View institutional ownership trends
.

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/05/2025
Today
9/10/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MLTX
CIK
1821586
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

High Price Target
$100.00
Low Price Target
$61.00
Potential Upside/Downside
+32.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.94 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.98%
Return on Assets
-35.81%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
16.65
Quick Ratio
16.65

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.09 per share
Price / Book
7.94

Miscellaneous

Outstanding Shares
64,230,000
Free Float
56,491,000
Market Cap
$3.61 billion
Optionable
Optionable
Beta
1.27
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:MLTX) was last updated on 9/10/2025 by MarketBeat.com Staff
From Our Partners